Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

320 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 disease.
Keller SM, Vangel MG, Wagner H, Schiller JH, Herskovic A, Komaki R, Marks RS, Perry MC, Livingston RB, Johnson DH; Eastern Cooperative Oncology Group. Keller SM, et al. Among authors: livingston rb. J Thorac Cardiovasc Surg. 2004 Jul;128(1):130-7. doi: 10.1016/j.jtcvs.2003.11.061. J Thorac Cardiovasc Surg. 2004. PMID: 15224032 Free article. Clinical Trial.
Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590.
Wakelee HA, Stephenson P, Keller SM, Wagner H, Herskovic A, Komaki R, Marks RS, Perry MC, Livingston RB, Johnson DH; Eastern Cooperative Oncology Group. Wakelee HA, et al. Among authors: livingston rb. Lung Cancer. 2005 Jun;48(3):389-97. doi: 10.1016/j.lungcan.2004.11.007. Epub 2005 Jan 5. Lung Cancer. 2005. PMID: 15893008 Clinical Trial.
A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group.
Keller SM, Adak S, Wagner H, Herskovic A, Komaki R, Brooks BJ, Perry MC, Livingston RB, Johnson DH. Keller SM, et al. Among authors: livingston rb. N Engl J Med. 2000 Oct 26;343(17):1217-22. doi: 10.1056/NEJM200010263431703. N Engl J Med. 2000. PMID: 11071672 Free article. Clinical Trial.
Similar outcome of elderly patients in intergroup trial 0096: Cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma.
Yuen AR, Zou G, Turrisi AT, Sause W, Komaki R, Wagner H, Aisner SC, Livingston RB, Blum R, Johnson DH. Yuen AR, et al. Among authors: livingston rb. Cancer. 2000 Nov 1;89(9):1953-60. doi: 10.1002/1097-0142(20001101)89:9<1953::aid-cncr11>3.3.co;2-y. Cancer. 2000. PMID: 11064352
Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy.
Schiller JH, Adak S, Feins RH, Keller SM, Fry WA, Livingston RB, Hammond ME, Wolf B, Sabatini L, Jett J, Kohman L, Johnson DH. Schiller JH, et al. Among authors: livingston rb. J Clin Oncol. 2001 Jan 15;19(2):448-57. doi: 10.1200/JCO.2001.19.2.448. J Clin Oncol. 2001. PMID: 11208838 Clinical Trial.
320 results